{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:28:17Z","timestamp":1780450097677,"version":"3.54.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Serotonin toxicity (also referred to as serotonin syndrome) results from medications that affect the neurotransmitter serotonin. The antibiotic linezolid and the opioids methadone and buprenorphine are all reported to cause serotonin toxicity, but the degree of risk with use of linezolid in combination with methadone or buprenorphine is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective cross-sectional analysis of adult patients hospitalized from November 2015 to October 2019 who were administered linezolid in combination with methadone and\/or buprenorphine within 24 hours and a subgroup that received the combination for \u22653 days. Cases of serotonin toxicity were identified from the clinical notes in the electronic medical record and were classified as possible or definite based on the clinical record. The Hunter diagnostic criteria were retrospectively applied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 494 encounters in which linezolid was administered concurrently with methadone and buprenorphine. The mean patient age was 42.5 years, and 52.4% of encounters were of female patients. The mean duration of concurrent administration was 1.9 days. There were 106 encounters with a duration of concurrent administration\u2009\u22653 days (mean, 5.4 days). Two cases of possible serotonin toxicity and 0 cases of definite serotonin toxicity occurred; neither possible case met the Hunter criteria from the available information. Possible cases occurred in 0.40% of all encounters and 1.89% of encounters with\u2009\u22653 days of overlap (upper 1-sided 95% CI, 0.87% and 4.06%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Serotonin toxicity occurring during the administration of linezolid in combination with methadone and\/or buprenorphine occurred rarely among 494 hospital encounters, including 106 encounters with\u2009\u22653 days of overlap. Limitations include potential missed diagnoses of serotonin toxicity and short durations of overlap. Further study evaluating the short-term risk of this combination is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac331","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T14:59:09Z","timestamp":1656687549000},"source":"Crossref","is-referenced-by-count":15,"title":["A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-3872","authenticated-orcid":false,"given":"Edward C","family":"Traver","sequence":"first","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-6684","authenticated-orcid":false,"given":"Emily L","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Schmalzle","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Maryland School of Medicine , Baltimore, Maryland , USA"},{"name":"Institute of Human Virology, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"2022072511115755800_ofac331-B1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"2022072511115755800_ofac331-B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1086\/320879","article-title":"Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study","volume":"33","author":"Murphy","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2022072511115755800_ofac331-B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/109629603764655290","article-title":"Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial","volume":"4","author":"Li","year":"2003","journal-title":"Surg Infect"},{"key":"2022072511115755800_ofac331-B4","doi-asserted-by":"publisher","first-page":"1669\u201374","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","author":"Hepburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"2022072511115755800_ofac331-B5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40121-018-0211-4","article-title":"Efficacy and safety of tedizolid and linezolid for the treatment of acute bacterial skin and skin structure infections in injection drug users: analysis of two clinical trials","volume":"7","author":"Moran","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2022072511115755800_ofac331-B6","article-title":"FDA drug safety communication: FDA warns about several safety issues with opioid pain medicines; requires label changes","author":"Food and Drug Administration","year":"2016"},{"key":"2022072511115755800_ofac331-B7","article-title":"FDA drug safety communication: updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications","author":"Food and Drug Administration","year":"2011"},{"key":"2022072511115755800_ofac331-B8","volume-title":"UpToDate","author":"Boyer"},{"key":"2022072511115755800_ofac331-B9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1345\/aph.1R386","article-title":"Clinical relevance of linezolid-associated serotonin toxicity","volume":"47","author":"Woytowish","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2022072511115755800_ofac331-B10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2022072511115755800_ofac331-B11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/jac\/dkr467","article-title":"Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data","volume":"67","author":"Butterfield","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2022072511115755800_ofac331-B12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JCP.0000000000000751","article-title":"Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy","volume":"37","author":"Karkow","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"2022072511115755800_ofac331-B13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/bph.14105","article-title":"Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome","volume":"175","author":"Rickli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2022072511115755800_ofac331-B14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00228-020-02990-1","article-title":"Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic\/pharmacodynamic analysis","volume":"77","author":"Gatti","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2022072511115755800_ofac331-B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2146\/ajhp060227","article-title":"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine","volume":"64","author":"Steinberg","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"2022072511115755800_ofac331-B16","first-page":"263","article-title":"Serotonin syndrome due to co-administration of linezolid and methadone","volume":"25","author":"Mastroianni","year":"2017","journal-title":"Infez Med"},{"key":"2022072511115755800_ofac331-B17","first-page":"1263","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"2022072511115755800_ofac331-B18","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMra1807054","article-title":"Prevention of opioid overdose","volume":"380","author":"Babu","year":"2019","journal-title":"N Engl J Med"},{"key":"2022072511115755800_ofac331-B19","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"Suppl 5","key":"2022072511115755800_ofac331-B20","doi-asserted-by":"publisher","first-page":"S513","DOI":"10.1093\/infdis\/jiz516","article-title":"A comparison of medication for opioid use disorder treatment strategies for persons who inject drugs with invasive bacterial and fungal infections","volume":"222","author":"Marks","year":"2020","journal-title":"J Infect Dis"},{"key":"2022072511115755800_ofac331-B21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","article-title":"Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis","volume":"129","author":"Rosenthal","year":"2016","journal-title":"Am J Med"},{"key":"2022072511115755800_ofac331-B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/ADM.0000000000000454","article-title":"Substance use disorder assessment, diagnosis, and management for patients hospitalized with severe infections due to injection drug use","volume":"13","author":"Jicha","year":"2019","journal-title":"J Addict Med"},{"key":"2022072511115755800_ofac331-B23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2008.08.009","article-title":"Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey","volume":"62","author":"Beekmann","year":"2008","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac331\/44372795\/ofac331.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac331\/45055824\/ofac331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac331\/45055824\/ofac331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T11:12:17Z","timestamp":1658747537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac331\/6625822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac331","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,7,1]]},"article-number":"ofac331"}}